GLG News by Physicians who Treat Atopic Eczema (US)
Request a free trial
April 23, 2007Altabax will have good sales in the impetigo market
Analysis of: FDA Approves Antibiotic Ointment For Children And Adults - Altabax (retapamulin Ointment) | www.medicalnewstoday.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Altabax (retapamulin) will be a competitive topical agent for impetigo because it is a new molecular entity, Bactroban or mupirocin is generic and cannot compete directly, and it is indicated for children as young as 9 months. The market for a nonoral antibiotic is always good, due to lower side ef...
April 23, 2007
PROPER USES OF TOPICAL ANTIBIOTICS, SEE BELOW
Analysis of: FDA Approves Antibiotic Ointment For Children And Adults - Altabax (retapamulin Ointment) | www.medicalnewstoday.com
Author: GLG Expert Contributor
Analysis of: FDA Approves Antibiotic Ointment For Children And Adults - Altabax (retapamulin Ointment) | www.medicalnewstoday.com
Author: GLG Expert Contributor
WHAT ARE THE PROPER USES OF ANTIBIOTICS ON INFECTED SITES, "CLEAN SITES", POST-OP SITES, ETC.?AN ANALYSIS OF TODAY'S THINKING.FOR IMPETIGO IT WILL BE USED, IT WILL NOT REPLACE EXISTING MODALITIES, BUT WILL SUPPLEMENT, AND HAVE THE ADVANTAGE OF NOT BEING USED SYSTEMICALLY.ROBERT AUERBACH, MD
April 23, 2007ELEVESS gets CE mark approval
Analysis of: Anika Gets CE Mark Certification For Commercial Sale Of Cosmetic Dermatology Product, ELEVESS In European Union | www.tradingmarkets.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...
April 23, 2007
ANOTHER FILLER, PROS AND CONS
Analysis of: Anika Gets CE Mark Certification For Commercial Sale Of Cosmetic Dermatology Product, ELEVESS In European Union | www.tradingmarkets.com
Author: GLG Expert Contributor
Analysis of: Anika Gets CE Mark Certification For Commercial Sale Of Cosmetic Dermatology Product, ELEVESS In European Union | www.tradingmarkets.com
Author: GLG Expert Contributor
IT MAY LAST LONGER, PROBABLY MORE EXPENSIVE, INJECTION TECHNIQUE MAY BE MORE CRITICAL IF IT LAST LONGER, I.E. MORE VISCOUS LESS MALLEABLE. HOW MUCH CLINICAL DATA IS AVAILABLE?HAVING USED FILLER MATERIAL FOR OVER 25 YEARS I HAVE EXPERIENCE WITH ALL OF THEM LONG-TERM.ROBERT AUERBACH, MD
April 4, 2007Collagenex Incyclinide phase 2 data released
Analysis of: CollaGenex Pharmaceuticals Announces Positive Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Acne | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...
March 23, 2007Gadolinium agents linked to NFD
Analysis of: Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This and other studies are highly suggestive that Gadolinium agents used in radiographic studies are associated with NFD. A large scale study should be initiated to confirm this association, and for now these agents should be avoided in patients with renal disease.
March 23, 2007The Black box warning of the Calcineurin inhibitors is faulty
Analysis of: Black Box Warning for Topical Calcineurin Inhibitors and the Death of Common Sense | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
I totally agree with this article. The conclusions from the FDA are incorrect, and the data appear to indicate that the TCI's are actually protective!!!! In any event it has created a false sense of a problem, where none exists, and decreases the use of these agents, which are safer than the existing...
March 23, 2007Acne scarring an under treated condition
Analysis of: Treatment of Acne Scarring | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is a good summary of the currently available techniques of excision, subcision, and resurfacing. It does not mention dermal grafting, a technique that I personally use quite often. The maximum correction that one can achieve is 50-70% with a combination of multiple techniques.
March 19, 2007
Whose performance are we counting?
Analysis of: Rethinking criteria for doctors' pay | www.chicagotribune.com
Author: GLG Expert Contributor
Analysis of: Rethinking criteria for doctors' pay | www.chicagotribune.com
Author: GLG Expert Contributor
1. P4P puts the burden on the physician without involving the patient.2. P4P creates yet another potential conflict of interest in patient care.3. P4P probably will not decrease costs or improve health.
March 19, 2007Cytochroma Cta018 cream
Analysis of: Cytochroma Completes Enrollment In Phase II Psoriasis Trial | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This product by Cytochroma is a vitamin D analog which is similar to Dovonex, a product that has been used for 13 years. Its efficacy is modest at best. This product may, repeat may be better, because it activates the vitamin D pathway, and inhibits catabolism of Vitamin D. Whether this makes the product...
Previous Page : 1 2 3 4 5 6 7 8 Next61 to 70 of 80
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

